Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells

Cancer Research

Volumn 71, Issue 9, 2011, Pages 3400-3409

  Ahmad, Aamir ^a   Aboukameel, Amro ^a   Kong, Dejuan ^a   Wang, Zhiwei ^a   Sethi, Seema ^a   Chen, Wei ^a   Sarkar, Fazlul H ^a   Raz, Avraham ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOCRINE MOTILITY FACTOR; CELL MARKER; GLUCOSE 6 PHOSPHATE ISOMERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; PROTEIN ZEB1; PROTEIN ZEB2; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; CELL MOTILITY; CLONOGENESIS; CONTROLLED STUDY; DNA BINDING; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

AUTOCRINE MOTILITY FACTOR; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GLUCOSE-6-PHOSPHATE ISOMERASE; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; MICRORNAS; NF-KAPPA B; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; UP-REGULATION;

EID: 79955497173     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0965     Document Type: Article

References (46)

1. Kim JW, Dang CV. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 2005;30:142-50. (Pubitemid 40332530)
2. Watanabe H, Takehana K, Date M, Shinozaki T, Raz A. Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res 1996;56:2960-3. (Pubitemid 26199739)
3. Niinaka Y, Paku S, Haga A, Watanabe H, Raz A. Expression and secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells. Cancer Res 1998;58: 2667-74. (Pubitemid 28275442)
4. Faik P, Walker JI, Redmill AA, Morgan MJ. Mouse glucose-6-phosphate isomerase and neuroleukin have identical 3′ sequences. Nature 1988;332:455-7.
5. Xu W, Seiter K, Feldman E, Ahmed T, Chiao JW. The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase. Blood 1996;87:4502-6. (Pubitemid 26162355)
6. Yakirevich E, Naot Y. Cloning of a glucose phosphate isomerase/ neuroleukin-like sperm antigen involved in sperm agglutination. Biol Reprod 2000;62:1016-23. (Pubitemid 30173816)
7. Cao MJ, Osatomi K, Matsuda R, Ohkubo M, Hara K, Ishihara T. Purification of a novel serine proteinase inhibitor from the skeletal muscle of white croaker (Argyrosomus argentatus). Biochem Biophys Res Commun 2000;272:485-9. (Pubitemid 30444644)
8. Yanagawa T, Funasaka T, Tsutsumi S, Watanabe H, Raz A. Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy. Endocr Relat Cancer 2004;11:749-59. (Pubitemid 40065548)
9. Chiu CG, St-Pierre P, Nabi IR, Wiseman SM. Autocrine motility factor receptor: a clinical review. Expert Rev Anticancer Ther 2008;8:207-17. (Pubitemid 351385912)
10. Jiang WG, Raz A, Douglas-Jones A, Mansel RE. Expression of autocrine motility factor (AMF) and its receptor AMFR in human breast cancer. J Histochem Cytochem 2006;54:231-41. (Pubitemid 43201644)
11. Funasaka T, Hu H, Yanagawa T, Hogan V, Raz A. Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells. Cancer Res 2007;67:4236-43. (Pubitemid 46815070)
12. Funasaka T, Hogan V, Raz A. Phosphoglucose isomerase/autocrine motility factor mediates epithelial and mesenchymal phenotype conversions in breast cancer. Cancer Res 2009;69:5349-56.
13. Niinaka Y, Harada K, Fujimuro M, Oda M, Haga A, Hosoki M, et al. Silencing of autocrine motility factor induces mesenchymal-to-epithelial transition and suppression of osteosarcoma pulmonary metastasis. Cancer Res 2010;70:9483-93.
14. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
15. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006;66:8319-26. (Pubitemid 44449137)
16. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Twist a master regulator of morphogenesis plays an essential role in tumor metastasis. Cell 2004;117:927-39. (Pubitemid 38798858)
17. Trimboli AJ, Fukino K, de Bruin A, Wei G, Shen L, Tanner SM, Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 2008;68:937-45. (Pubitemid 351206773)
18. Talukder AH, Adam L, Raz A, Kumar R. Heregulin regulation of autocrine motility factor expression in human tumor cells. Cancer Res 2000;60:474-80. (Pubitemid 30070778)
19. Talukder AH, Bagheri-Yarmand R, Williams RR, Ragoussis J, Kumar R, Raz A. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors. Clin Cancer Res 2002;8:3285-9. (Pubitemid 35155042)
20. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, et al. Four miRNAs associated with aggressiveness of lymph node-negative estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A 2008;105:13021-6.
21. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449:682-8. (Pubitemid 47552092)
22. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10: 593-601. (Pubitemid 351627379)
23. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, et al. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition adhesion and invasion of prostate cancer cells. Stem Cells 2009;27:1712-21.
24. Ahmad A, Banerjee S, Wang Z, Kong D, Sarkar FH. Plumbagininduced apoptosis of human breast cancer cells is mediated by inactivation of NF-kappaB and Bcl-2. J Cell Biochem 2008;105: 1461-71.
25. Ahmad A, Wang Z, Kong D, Ali S, Li Y, Banerjee S, et al. FoxM1 downregulation leads to inhibition of proliferation migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat 2010;122:337-46.
26. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-9. (Pubitemid 351550859)
27. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 2007;26: 711-24. (Pubitemid 46204250)
28. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004;114:569-81. (Pubitemid 39572107)
29. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine- resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009;69:2400-7.
30. Jo M , Lester RD, Montel V, Eastman B, Takimoto S, Gonias SLReversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem 2009;284:22825-33.
31. Orlichenko LS, Radisky DC. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis 2008;25:593-600.
32. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the Ecadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22:894-907. (Pubitemid 351482843)
33. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008;283:14910-4.
34. Liotta LA, Mandler R, Murano G, Katz DA, Gordon RK, Chiang PK, et al. Tumor cell autocrine motility factor. Proc Natl Acad Sci U S A 1986;83:3302-6. (Pubitemid 16043024)
35. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001;294: 853-8. (Pubitemid 33032103)
36. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001;294:858-62. (Pubitemid 33032104)
37. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001;294:862-4. (Pubitemid 33032105)
38. Funasaka T, Raz A. The role of autocrine motility factor in tumor and tumor microenvironment. Cancer Metastasis Rev 2007;26:725-35. (Pubitemid 350115116)
39. Shi M, Guo N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev 2009;35:328-34.
40. Sarkar FH, Li Y, Wang Z, Kong D. NF-kappaB signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol 2008;27:293-319.
41. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009;15:416-28.
42. Croce CM . Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10:704-14.
43. Korpal M, Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 2008;5:115-9.
44. Li Y, VandenBoom TG, Kong D, Wang Z, Ali S, Philip PA, et al. Upregulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabineresistant pancreatic cancer cells. Cancer Res 2009;69:6704-12.
45. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008;68:7846-54.
46. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR- 200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008;9:582-9. (Pubitemid 351772923)